Menopause Supplements With Evidence: What Actually Works

Why the Supplement Market Outpaces the Science

The menopause supplement industry generates billions annually, but the clinical evidence supporting most products is thin. A 2023 review published in Climacteric found that fewer than 30% of supplements marketed for hot flash relief had been tested in placebo-controlled trials with more than 100 participants [1]. The gap between marketing and data is wide.

The North American Menopause Society (NAMS) stated in its 2022 Position Statement: "Hormone therapy remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause (GSM)" [2]. That position has not changed. For women who cannot or prefer not to use HRT, several supplements do carry meaningful evidence, but "meaningful" requires specifics: named trials, defined doses, and measurable effect sizes.

This guide evaluates each supplement against its best available RCT and meta-analysis data, not testimonials or mechanistic reasoning alone. Where evidence is absent or negative, we say so directly. Supplements are not regulated with the same rigor as prescription drugs by the FDA, and quality control varies between manufacturers [3].

Soy Isoflavones: The Strongest Non-Hormonal Signal

Soy isoflavones are the best-studied non-prescription option for hot flash reduction, though results depend heavily on gut microbiome composition. A 2012 meta-analysis by Taku et al., pooling 17 RCTs and 2,139 women, found that soy isoflavone supplementation reduced hot flash frequency by 20.6% and severity by 26.2% compared with placebo [4]. The effective dose range across trials was 40 to 80 mg of isoflavones daily, with benefits typically emerging after 6 to 12 weeks.

The catch is S-equol. This active metabolite of the soy isoflavone daidzein is produced by specific intestinal bacteria, and only about 25 to 30% of Western women are natural S-equol producers [5]. Equol producers appear to derive greater benefit from soy supplementation. A 2015 RCT (N=102) testing a direct S-equol supplement (10 mg three times daily) in non-equol-producing postmenopausal women found a statistically significant reduction in hot flash frequency and severity compared with placebo [6].

Genistein, the other major soy isoflavone, has also been studied independently. A 2007 RCT (N=389) published in Annals of Internal Medicine tested 54 mg of genistein daily and found a significant reduction in hot flash frequency at 12 months compared with placebo, with no endometrial safety signals on biopsy [7]. Women considering soy isoflavones should know that whole soy foods and concentrated supplements are not interchangeable; the isoflavone content of tofu or edamame varies considerably by preparation.

Black Cohosh: Popular but Inconsistent

Black cohosh (Cimicifuga racemosa) is the most commonly purchased herbal menopause supplement in North America. The evidence, however, does not match its popularity.

A 2012 Cochrane review examined 16 RCTs of black cohosh for menopausal symptoms. The authors concluded: "There is insufficient evidence to support the use of black cohosh for menopausal symptoms" due to heterogeneous trial designs, small sample sizes, and inconsistent outcome measures [8]. Some individual trials did report modest short-term hot flash reductions at doses of 20 to 40 mg of standardized extract daily, but the pooled analysis could not confirm a reliable effect.

The German Commission E historically approved black cohosh for climacteric complaints, and a few European trials using the proprietary extract Remifemin (20 mg isopropanolic extract twice daily) have shown positive results over 12-week periods [9]. Safety data are reassuring for short-term use (up to 6 months), though rare case reports of hepatotoxicity have prompted the FDA to recommend label warnings. Women with liver disease should avoid it. The American College of Obstetricians and Gynecologists (ACOG) lists black cohosh as a potential option but stops short of a strong recommendation [10].

Calcium and Vitamin D: Bone Protection, Not Symptom Relief

These two nutrients do not treat hot flashes, night sweats, or mood changes. Their role in menopause care is specific: preventing the accelerated bone loss that follows estrogen decline. Postmenopausal women lose 1 to 2% of bone mineral density (BMD) per year during the first 5 to 7 years after menopause [11].

The Endocrine Society's 2019 Clinical Practice Guideline recommends 1,000 to 1 to 200 mg of elemental calcium daily (diet plus supplements) and 600 to 800 IU of vitamin D for postmenopausal women not on osteoporosis pharmacotherapy [11]. The Women's Health Initiative (WHI) calcium/vitamin D trial (N=36,282) found that supplementation with 1 to 000 mg calcium and 400 IU vitamin D daily produced a small but significant 1.06% improvement in hip BMD over 7 years, though it did not significantly reduce hip fracture risk in the intention-to-treat analysis [12]. Adherence was a major confounder: among women who took at least 80% of their assigned pills, hip fracture risk dropped by 29%.

Dr. JoAnn Manson, lead investigator on multiple WHI analyses, has noted: "Calcium and vitamin D supplementation should be considered foundational for skeletal health in postmenopausal women, but it is not a substitute for pharmacologic therapy in those with established osteoporosis" [12]. Vitamin D levels should be checked; a serum 25(OH)D target of 30 to 50 ng/mL is widely recommended.

Vaginal DHEA (Prasterone): FDA-Approved for a Reason

Unlike most items on this list, vaginal DHEA (prasterone, brand name Intrarosa) holds FDA approval for moderate-to-severe dyspareunia due to vulvovaginal atrophy (VVA) in postmenopausal women [13]. It is not a dietary supplement; it is a regulated drug. But because DHEA is also sold over the counter in oral form and marketed for menopause, clarifying the evidence matters.

The key trial (ERC-231, N=325) randomized postmenopausal women with VVA to daily vaginal inserts containing 6.5 mg DHEA or placebo. At 12 weeks, DHEA significantly improved vaginal pH, increased superficial cells on maturation index, and reduced pain during intercourse. Serum estrogen levels remained within the normal postmenopausal range [13]. A follow-up 52-week open-label study confirmed sustained efficacy and safety [14].

Oral DHEA is a different matter entirely. A 2015 systematic review in Maturitas found no consistent evidence that oral DHEA supplementation (25 to 50 mg daily) improved hot flashes, mood, or sexual function in postmenopausal women [15]. The distinction between vaginal and oral delivery is not trivial; local conversion to estrogen and testosterone in vaginal tissue drives the benefit. Women interested in DHEA for GSM symptoms should specifically ask about the vaginal formulation.

Melatonin: A Sleep-Specific Tool

Sleep disruption affects 40 to 60% of perimenopausal and postmenopausal women, driven by a combination of vasomotor symptoms, circadian rhythm changes, and declining endogenous melatonin production [16]. Exogenous melatonin has been studied for this specific complaint.

A 2022 double-blind RCT (N=60) published in Menopause tested 3 mg of prolonged-release melatonin nightly in perimenopausal women with insomnia. After 12 weeks, the melatonin group showed a 15-minute improvement in sleep onset latency and a significant increase in total sleep time compared with placebo, with no morning grogginess or rebound effects [17]. The effect size is modest. It is real.

The Endocrine Society has not issued a formal guideline on melatonin for menopause-related insomnia, but a 2020 meta-analysis of melatonin for primary insomnia in adults (19 RCTs, N=1,683) found a pooled reduction in sleep onset latency of 7.06 minutes [18]. Doses of 2 to 5 mg taken 30 to 60 minutes before bed are most commonly studied. Melatonin does not treat hot flashes, and it should not be combined with sedative-hypnotics without physician oversight.

Supplements That Do Not Hold Up

Several widely marketed menopause supplements have failed to outperform placebo in rigorous trials. Knowing what does not work is as valuable as knowing what does.

Omega-3 fatty acids. A 2013 RCT published in JAMA Internal Medicine (N=355) randomized women with moderate-to-severe hot flashes to 1.8 g/day of omega-3 fatty acids or placebo for 12 weeks. There was no difference in hot flash frequency, severity, or interference between groups [19]. The trial was adequately powered and well-designed. Omega-3s carry cardiovascular and anti-inflammatory benefits, but hot flash relief is not among them.

Red clover isoflavones. A Cochrane review of five RCTs found no significant difference between red clover (Trifolium pratense) isoflavone supplements and placebo for hot flash frequency or severity [8]. Individual trials used doses of 40 to 160 mg daily. The isoflavone profile of red clover differs from soy (biochanin A and formononetin predominate), which may explain the divergent results.

Evening primrose oil. A 2013 RCT (N=56) found no significant difference between evening primrose oil and placebo for hot flash severity over 6 weeks [20]. The gamma-linolenic acid mechanism has not been validated for vasomotor symptom relief.

Dong quai. A 1997 RCT (N=71) published in Fertility and Sterility found no benefit of dong quai over placebo for hot flashes, endometrial thickness, or maturation index [21]. Despite continued availability, the evidence base is essentially unchanged after 25+ years.

Maca root. Preliminary studies are small (N < 50) and methodologically limited. A 2011 Cochrane-style review found insufficient evidence to recommend maca for menopause symptoms [22]. The hype substantially exceeds the data.

Building a Rational Supplement Plan

For women who cannot or choose not to use HRT, the following hierarchy reflects the current evidence base, moving from strongest to weakest support.

First-line non-hormonal option for VMS: discuss prescription alternatives (fezolinetant, low-dose paroxetine, gabapentin) with a clinician before relying on supplements. These carry stronger and more consistent evidence than any OTC product [2].

For hot flashes specifically, soy isoflavones (40 to 80 mg daily, standardized extract) represent the most evidence-supported supplement option, with the caveat that response depends on S-equol producer status [4]. Women who do not respond after 12 weeks are unlikely to be equol producers and should discontinue.

For bone health, calcium (1,000 to 1 to 200 mg daily from all sources) and vitamin D (600 to 2 to 000 IU daily, titrated to serum 25(OH)D of 30+ ng/mL) should be considered standard postmenopausal care regardless of HRT status [11].

For GSM/vaginal dryness, vaginal DHEA (prasterone 6.5 mg nightly) is an FDA-approved option that does not raise systemic hormone levels [13].

For sleep disruption, melatonin (2 to 5 mg prolonged-release, 30 to 60 minutes before bed) carries modest but real RCT support [17].

Black cohosh (20 to 40 mg standardized extract daily) may be tried for up to 6 months, but expectations should be calibrated to the inconsistent evidence. The NAMS 2022 Position Statement notes that "recommendations for the use of black cohosh are limited by inconsistent data" [2].

All supplement use should be disclosed to prescribing physicians, particularly for women on anticoagulants, tamoxifen, or thyroid medications, where interactions are documented.